CPRXCPRX
US • —
$31.46
P/E
18.08
PEG
1.69
FCF Yield
—
Rev Growth YoY
+11.7% YoY
Gross Margin
86.0%
Health Score
9/10
D/E Ratio
—
Confidence
LOW
Business Snapshot
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neurological and neuromuscular diseases. Its primary revenue-generating product is Firdapse (amifampridine), approved for Lambert-Eaton myasthenic syndrome (LEMS) and also being investigated for other neuromuscular conditions. The company operates as a niche leader in the orphan drug space, benefiting from regulatory exclusivity and a focused commercial strategy. Financial scale data is not available, preventing a definitive market cap tier classification. The defining characteristic is its high-margin orphan drug business model, which supports strong profitability despite a relatively narrow product portfolio.
Financial Health
Catalyst Pharmaceuticals carries no debt, with a Debt/Equity ratio of 0.0x, reflecting a fortress balance sheet with significant financial flexibility. The current ratio of 6.08x indicates ample short-term liquidity, well above the 1.0x threshold typically considered healthy...
Risk Assessment
- VALUATION DIVERGENCE — A DCF estimate was not available, preventing a model-based assessment of intrinsic value versus the current price.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- CONCENTRATION — The company's revenue is dependent on a single approved product (Firdapse) for a niche indication, creating business risk from regulatory or competitive changes....
Catalyst Pharmaceuticals carries no debt, with a Debt/Equity ratio of 0.0x, reflecting a fortress balance sheet with significant financial flexibility. The current ratio of 6.08x indicates ample short-term liquidity, well above the 1.0x threshold typically considered healthy. Gross margins stand at 86.0%, a very high level characteristic of a low-cost pharmaceutical manufacturing model, while net margins of 37.1% demonstrate efficient conversion of revenue to profit. Free cash flow data is not available, preventing assessment of cash generation or burn. Overall, the company is in an exceptionally strong financial position, with the capacity to fund internal R&D, pursue strategic acquisitions, and potentially return capital to shareholders without reliance on external financing.
- VALUATION DIVERGENCE — A DCF estimate was not available, preventing a model-based assessment of intrinsic value versus the current price. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - CONCENTRATION — The company's revenue is dependent on a single approved product (Firdapse) for a niche indication, creating business risk from regulatory or competitive changes.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives